All News

2018

July

Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

June

Media Release / Jun 29, 2018

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe

Read More
Media Release / Jun 16, 2018

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Read More
Media Release / Jun 15, 2018

Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Read More
Media Release / Jun 15, 2018

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

Read More
Story / Jun 13, 2018

Women in Science: Kristen Harrington-Smith

Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

Read More
Media Release / Jun 07, 2018

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

Read More
Media Release / Jun 03, 2018

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Read More
Media Release / Jun 02, 2018

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More